Corvus Pharmaceuticals (NASDAQ:CRVS) Given Outperform Rating at Oppenheimer

Corvus Pharmaceuticals (NASDAQ:CRVS)‘s stock had its “outperform” rating reissued by investment analysts at Oppenheimer in a research note issued to investors on Friday,Benzinga reports. They currently have a $33.00 target price on the stock, up from their prior target price of $32.00. Oppenheimer’s price target indicates a potential upside of 118.83% from the stock’s current price.

A number of other equities analysts have also weighed in on CRVS. Mizuho set a $30.00 target price on Corvus Pharmaceuticals in a research note on Thursday, January 29th. Jefferies Financial Group increased their target price on shares of Corvus Pharmaceuticals from $13.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Cantor Fitzgerald reissued an “overweight” rating on shares of Corvus Pharmaceuticals in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research note on Wednesday, January 21st. Finally, HC Wainwright raised their price target on Corvus Pharmaceuticals from $11.00 to $27.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Corvus Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $32.00.

Corvus Pharmaceuticals Stock Down 5.8%

Shares of NASDAQ:CRVS traded down $0.93 during midday trading on Friday, reaching $15.08. 604,059 shares of the company were exchanged, compared to its average volume of 3,925,115. The firm has a market cap of $1.26 billion, a PE ratio of -28.50 and a beta of 0.78. The stock has a fifty day simple moving average of $16.30 and a two-hundred day simple moving average of $10.47. Corvus Pharmaceuticals has a fifty-two week low of $2.54 and a fifty-two week high of $26.95.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). As a group, analysts forecast that Corvus Pharmaceuticals will post -0.63 earnings per share for the current year.

Hedge Funds Weigh In On Corvus Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Corvus Pharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,629 shares of the company’s stock worth $28,000 after buying an additional 748 shares during the last quarter. Quarry LP bought a new position in shares of Corvus Pharmaceuticals in the 3rd quarter valued at $27,000. Russell Investments Group Ltd. acquired a new stake in shares of Corvus Pharmaceuticals during the 3rd quarter valued at $49,000. Truvestments Capital LLC grew its position in Corvus Pharmaceuticals by 86.1% during the 4th quarter. Truvestments Capital LLC now owns 10,257 shares of the company’s stock worth $79,000 after acquiring an additional 4,744 shares during the last quarter. Finally, Captrust Financial Advisors bought a new stake in Corvus Pharmaceuticals during the 4th quarter worth $85,000. Institutional investors own 46.64% of the company’s stock.

More Corvus Pharmaceuticals News

Here are the key news stories impacting Corvus Pharmaceuticals this week:

• Positive Sentiment: Corvus reported positive safety and efficacy results from cohort 4 of its soquelitinib Phase 1 atopic dermatitis trial, including responses in patients previously treated with systemic therapy — a meaningful validation of the asset and a potential de-risk for future development or partner interest. GlobeNewswire: Business Update & Q4 Results
• Neutral Sentiment: Management reviewed strategic advances and pipeline priorities on the Q4 2025 earnings call and in published transcripts; that commentary reiterates focus on clinical development and potential value-driving milestones but offered no major near-term commercial catalysts. Yahoo Finance: Q4 2025 Highlights
• Neutral Sentiment: Several earnings call transcripts and coverage are available for detail (call Q&A may have influenced sentiment); these provide nuance on cash runway, R&D priorities and timeline expectations but did not change guidance materially. Seeking Alpha: Call Transcript
• Negative Sentiment: Corvus reported Q4 EPS of ($0.15), missing the consensus of ($0.14) — the small miss, together with continued expected negative earnings for the year, likely pressured the stock despite the clinical news. MarketBeat: Q4 Earnings Summary
• Negative Sentiment: Market action suggests profit-taking and risk-off after the mixed release: clinical data supports longer-term upside but the near-term picture (EPS miss, no major commercial updates or new guidance) left traders selling into the announcement. Trading volume was below recent averages during the pullback. Investing.com: Market Reaction to Trial Data
• Neutral Sentiment: Reported short-interest figures in the feeds are inconsistent/erroneous (showing zero) and appear not to be a meaningful driver of today’s move. Investors should consult exchange short-interest reports for clarity.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.